Single intravenous CM559 dosing in healthy adult men
Official title: A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM559 in Healthy Subjects With Single Ascending Dose Administration
Run by Keymed Biosciences Co.Ltd · NCT07175506 · Data updated 2026-11-12
This trial tests single intravenous doses of CM559 to see if they are safe and how the drug is processed in healthy men aged 18–60.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | Men only |
| Enrollment | 40 (estimated) |
| Sponsor | Keymed Biosciences Co.Ltd Industry-sponsored |
| Locations | 1 site (Chengdu, Sichuan) |
| Status | Recruiting |
| Started | September 2025 |
| Main results expected | June 2026 |
| Study ends | June 2026 |
| Registry record updated | September 29, 2025 |
| Trial ID | NCT07175506 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy men aged 18–60 without recent heavy alcohol or drug use, limited cigarette use, no recent major surgery or significant blood loss, and no history of severe allergic reactions to monoclonal antibodies are ideal candidates.
✕Probably not a fit
People with active medical conditions, women (since only males are enrolled), heavy smokers, recent drug or alcohol users, recent major surgery or significant blood loss, or a history of severe allergic reactions to biologic drugs are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase I trial in healthy male volunteers. Participants receive one intravenous dose of CM559 or placebo at ascending dose levels with close safety monitoring. The study measures safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity following dosing. Results will inform safe dosing and design of later trials in patients.
Why it matters
Potential benefit: If results are favorable, the data could define safe dose ranges and support further trials that may lead to treatments using CM559.
How similar studies have gone: Single-dose, dose-escalation Phase I trials in healthy volunteers are a standard first step for monoclonal antibodies and have previously defined safe dosing and PK for many antibody drugs, though efficacy must be shown in later patient trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects age ≥ 18 years \& ≤60 years. * Subjects voluntarily signed the Informed Consent Form and were able to comply with the provisions of this protocol. Exclusion Criteria: * The average number of cigarettes smoked per day is greater than 5 within 3 months prior to screening. * Drinking heavily within 3 months prior to screening, or unable to guarantee not to drink alcohol during the research period, or positive alcohol breath testing. * History of drug abuse within 1 year prior to screening, or positive urine drug abuse screening. * Blood donation or any other form of blood loss exceeding 400mL, or accepting blood transfusion within 12 weeks prior to screening. * Suspected allergy to Aβ-antibody drugs, humanized monoclonal antibody drugs and their excipients, or other biological agents, or have a history of severe allergic reactions to other drugs. * Severe trauma or undergo major surgery within 3 months prior to screening,or planned surgery during the research period.
Where it's running
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China Recruiting
Study contacts
- Study coordinator: Qian Jia
- Email: qianjia@keymedbio.com
- Phone: 028-88610620
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bioequivalence comparison between YHP2508B and YHR2602 in healthy adults
This study tests whether YHP2508B and YHR2602 deliver similar amounts of the drug in healthy adults after a single dose.
-
Bioequivalence test of two drugs in healthy adults
This study tests whether YHP2508A and YHR2601 are bioequivalent in healthy volunteers.
-
Reactive Balance Training with Augmented Reality for Older Adults
This study tests whether reactive balance training using augmented reality helps older adults who are at risk of falling, compared with regular treadmill walking.
-
How the body responds to exercise with low oxygen in healthy adults
Researchers test how healthy men and women respond to different exercise types while breathing air with varying oxygen levels.
-
IS M8969 safety and PK/PD in healthy and at-risk adults
This early-phase study tests ISM8969 versus placebo to see if it is safe, well tolerated, and how the body handles and responds to it in healthy adults and obese adults at risk for heart disease.
-
Ear-based vagus nerve stimulation to improve reaction time
Researchers will try a short, noninvasive electrical stimulation of the vagus nerve at the ear to see if it shortens reaction time in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.